Lilly backs Topas' liver-specific nanoparticles platform

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Eli Lilly and Co. (NYSE:LLY) to develop therapeutics that induce antigen-specific immune tolerance. The companies will initially focus on undisclosed external antigens thought to be involved in autoimmune and inflammatory diseases.

The partners will harness Topas' platform which uses peptide-loaded nanoparticles to selectively target liver sinusoidal endothelial cells (LSECs)...